TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38910234

Group type: EXPERIMENTAL
Intervention: Social support intervention involving an informal caregiver, nurse consultations, and motivational text messages over 6 months.
Number of subjects: 464
Study: 38910557

Group type: EXPERIMENTAL
Intervention: 12-item Kansas City Cardiomyopathy Questionnaire (baseline assessment)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Oberst Caregiving Burden Scale (OCBS-time)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Oberst Caregiving Burden Scale (OCBS-difficulty)
Number of subjects: 162
Study: 38910596

Group type: EXPERIMENTAL
Intervention: Perceived social isolation
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Resilience
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Promotion of social connection and resilience
Number of subjects: 163
Study: 38910601

Group type: EXPERIMENTAL
Intervention: Aesthetic evaluation scale in patients with systemic sclerosis
Number of subjects: 88
Study: 38910891

Group type: EXPERIMENTAL
Intervention: Anaprazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ilaprazole
Number of subjects: 0
Study: 38910914

Group type: EXPERIMENTAL
Intervention: Algorithm-based screening program
Number of subjects: 769

Group type: COMPARATOR
Intervention: Reference group (non-obese)
Number of subjects: 769
Study: 38910942

Group type: EXPERIMENTAL
Intervention: High-risk aMCI group
Number of subjects: 176

Group type: COMPARATOR
Intervention: Low-risk aMCI group
Number of subjects: 176
Study: 38911348

Group type: EXPERIMENTAL
Intervention: 0.4 mg nicotine cigarettes
Number of subjects: 438
Study: 38911477

Group type: EXPERIMENTAL
Intervention: Heavy resistance training (HRT)
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Moderate-intensity training (MIT)
Number of subjects: 451

Group type: COMPARATOR
Intervention: Non-exercising control group (CON)
Number of subjects: 451
Study: 38911519

Group type: EXPERIMENTAL
Intervention: HCM patients
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 60
Study: 38911552

Group type: EXPERIMENTAL
Intervention: AA plus TEA
Number of subjects: 66

Group type: COMPARATOR
Intervention: AA plus sham TEA
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: AA plus TEA and AA plus sham TEA
Number of subjects: 66
Study: 38911584

Group type: EXPERIMENTAL
Intervention: autologous PRP
Number of subjects: 32

Group type: COMPARATOR
Intervention: steroid/anesthetic
Number of subjects: 32

Group type: COMPARATOR
Intervention: normal saline
Number of subjects: 32
Study: 38911647

Group type: EXPERIMENTAL
Intervention: Noncardiac surgery
Number of subjects: 36657

Group type: EXPERIMENTAL
Intervention: Cancer treatment in past 6 months
Number of subjects: 36657

Group type: EXPERIMENTAL
Intervention: Estimated glomerular filtration rate or on dialysis
Number of subjects: 36657

Group type: EXPERIMENTAL
Intervention: General surgery
Number of subjects: 36657

Group type: EXPERIMENTAL
Intervention: Stroke during index hospitalization
Number of subjects: 36657

Group type: EXPERIMENTAL
Intervention: Discharge to nursing home
Number of subjects: 36657
Study: 38911836

Group type: EXPERIMENTAL
Intervention: ActiveHip+ mHealth intervention
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 105
Study: 38911954

Group type: EXPERIMENTAL
Intervention: Affect labeling intervention
Number of subjects: 0
Study: 38912192

Group type: EXPERIMENTAL
Intervention: Photopneumatic device
Number of subjects: 30
Study: 38912228

Group type: EXPERIMENTAL
Intervention: ACS patients with high-CD4+ T cell trajectory
Number of subjects: 67

Group type: COMPARATOR
Intervention: ACS patients
Number of subjects: 67

Group type: COMPARATOR
Intervention: Chronic patients
Number of subjects: 67
Study: 38912296

Group type: EXPERIMENTAL
Intervention: Ustekinumab (UST) therapy
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: IUS parameters (B-mode, Doppler, dynamic CEUS, elastography)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: IUS score developed from ultrasound parameters
Number of subjects: 52
Study: 38912588

Group type: EXPERIMENTAL
Intervention: Gbe1ys/ys mouse model
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Clinical and histopathology data from patients with GSD IV
Number of subjects: 23

Group type: COMPARATOR
Intervention: Liver biopsy findings
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Postmortem liver pathology analysis
Number of subjects: 23
Study: 38912654

Group type: EXPERIMENTAL
Intervention: Tirzepatide (10 mg or 15 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38912692

Group type: EXPERIMENTAL
Intervention: Tailored aggressive hydration (TAH) - 20 mL/kg bolus post-ERCP and 3 mL/kg/hr during and after ERCP
Number of subjects: 344

Group type: COMPARATOR
Intervention: Tailored standard hydration (TSH) - 1.5 mL/kg/hr lactated Ringer's solution during and after ERCP
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Both groups assessed for elevated serum amylase levels and pain 4-6 hours after ERCP
Number of subjects: 344
Study: 38912697

Group type: EXPERIMENTAL
Intervention: Hybrid endoscopic submucosal dissection (H-ESD)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Conventional endoscopic submucosal dissection (C-ESD)
Number of subjects: 89
Study: 38912784

Group type: EXPERIMENTAL
Intervention: Laminoplasty (LP)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Anterior cervical decompression/fusion (ACDF)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Posterior cervical decompression/fusion (PCDF)
Number of subjects: 163

Group type: COMPARATOR
Intervention: PCDF
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Overall (all surgical approaches)
Number of subjects: 163
Study: 38912887

Group type: EXPERIMENTAL
Intervention: Hexaspline pulsed field ablation (PFA) catheter, delivering pulse intensities at PV ostium (1800 V) and atrium (2000 V)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Hexaspline pulsed field ablation (PFA) catheter
Number of subjects: 143
Study: 38912884

Group type: EXPERIMENTAL
Intervention: 5% human albumin solution (HAS)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Balanced crystalloid
Number of subjects: 301
Study: 38912905

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with high triglyceride to total cholesterol (TG/TC) ratio
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline serum TG/TC, TG/HDL and TG/LDL ratios
Number of subjects: 0
Study: 38912927

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) therapy
Number of subjects: 40
Study: 38913003

Group type: EXPERIMENTAL
Intervention: Semaglutide 2.4 mg
Number of subjects: 1145

Group type: COMPARATOR
Intervention: Semaglutide
Number of subjects: 1145
Study: 38913004

Group type: EXPERIMENTAL
Intervention: Semaglutide 2.4 mg
Number of subjects: 1145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1145
Study: 38913094

Group type: EXPERIMENTAL
Intervention: Non-invasive airway management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38913377

Group type: EXPERIMENTAL
Intervention: Intravascular imaging-guided PCI
Number of subjects: 1639

Group type: COMPARATOR
Intervention: Angiography-guided PCI
Number of subjects: 1639

Group type: EXPERIMENTAL
Intervention: Intravascular imaging-guided PCI with good glycemic control (HbA1c ≤7.5%)
Number of subjects: 1639
Study: 38913539

Group type: EXPERIMENTAL
Intervention: Lanreotide autogel/depot (120 mg every 28 days) plus best supportive care (BSC)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo plus best supportive care (BSC)
Number of subjects: 77
Study: 38913574

Group type: EXPERIMENTAL
Intervention: Remdesivir (200 mg on day 1; 100 mg daily up to day 5)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Remdesivir
Number of subjects: 243
Study: 38913625

Group type: EXPERIMENTAL
Intervention: Mobile app intervention for mental health promotion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 60
Study: 38913710

Group type: EXPERIMENTAL
Intervention: VRC07-523LS IV 2.5 mg/kg
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: VRC07-523LS IV 5 mg/kg
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: VRC07-523LS IV 20 mg/kg
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: VRC07-523LS SC 2.5 mg/kg
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: VRC07-523LS SC 5 mg/kg
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: VRC07-523LS IM 2.5 mg/kg
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo IM
Number of subjects: 124
Study: 38913881

Group type: EXPERIMENTAL
Intervention: Neoadjuvant pembrolizumab plus chemotherapy (n=762)
Number of subjects: 762

Group type: EXPERIMENTAL
Intervention: Adjuvant pembrolizumab (n=539)
Number of subjects: 762

Group type: COMPARATOR
Intervention: Neoadjuvant placebo plus chemotherapy (n=383)
Number of subjects: 762

Group type: COMPARATOR
Intervention: Adjuvant placebo (n=308)
Number of subjects: 762
Study: 38913882

Group type: EXPERIMENTAL
Intervention: QuitBot (conversational chatbot)
Number of subjects: 179

Group type: COMPARATOR
Intervention: SmokefreeTXT (text messaging program)
Number of subjects: 179
Study: 38913933

Group type: EXPERIMENTAL
Intervention: Immunotherapy added to standard neoadjuvant chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard neoadjuvant chemotherapy
Number of subjects: 0
Study: 38913962

Group type: EXPERIMENTAL
Intervention: 18 F-DPA-714 PET/CT imaging
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Immunohistochemistry
Number of subjects: 13
Study: 38913998

Group type: COMPARATOR
Intervention: Pre-pandemic period (January to December 2019)
Number of subjects: 9031

Group type: COMPARATOR
Intervention: Early pandemic period (July 2020 to June 2021)
Number of subjects: 9031

Group type: COMPARATOR
Intervention: Late pandemic period (July 2021 to June 2022)
Number of subjects: 9031

Group type: EXPERIMENTAL
Intervention: Overall outcomes during the pandemic
Number of subjects: 9031

Group type: EXPERIMENTAL
Intervention: Witnessed arrest
Number of subjects: 9031

Group type: EXPERIMENTAL
Intervention: Arrest at home or residence
Number of subjects: 9031

Group type: EXPERIMENTAL
Intervention: Automated external defibrillator use by bystanders
Number of subjects: 9031

Group type: EXPERIMENTAL
Intervention: First monitored shockable rhythm
Number of subjects: 9031

Group type: EXPERIMENTAL
Intervention: Prehospital endotracheal intubation
Number of subjects: 9031

Group type: EXPERIMENTAL
Intervention: Time from cardiac arrest cognition to emergency department arrival
Number of subjects: 9031
Study: 38914016

Group type: EXPERIMENTAL
Intervention: 177 Lu-DOTATATE peptide receptor radionuclide therapy (PRRT)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 177 Lu-DOTATATE PRRT
Number of subjects: 37
Study: 38914085

Group type: EXPERIMENTAL
Intervention: Bailout angioplasty or stenting (BAOS)
Number of subjects: 348

Group type: COMPARATOR
Intervention: Standard therapy (continue or terminate the thrombectomy procedure)
Number of subjects: 348
Study: 38914124

Group type: EXPERIMENTAL
Intervention: Semaglutide
Number of subjects: 3533

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3533
Study: 38914224

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate/high-fat (LC) diet for 4 days
Number of subjects: 11

Group type: COMPARATOR
Intervention: High-carbohydrate/low-fat (HC) diet for 4 days
Number of subjects: 11
Study: 38914270

Group type: EXPERIMENTAL
Intervention: 2.5 mg rivaroxaban twice daily plus 100 mg aspirin daily
Number of subjects: 1000

Group type: COMPARATOR
Intervention: 100 mg aspirin daily
Number of subjects: 1000

Group type: COMPARATOR
Intervention: 5 mg rivaroxaban twice daily
Number of subjects: 1000
Study: 38914294

Group type: EXPERIMENTAL
Intervention: PDS with ranibizumab 100 mg/ml with fixed refill-exchanges every 24 weeks (Q24W)
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Supplemental intravitreal ranibizumab injections
Number of subjects: 418

Group type: COMPARATOR
Intervention: Monthly intravitreal ranibizumab 0.5 mg
Number of subjects: 418
Study: 38914309

Group type: EXPERIMENTAL
Intervention: Mindful Living (web-delivered psychosocial intervention)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Healthy Lifestyles (active control)
Number of subjects: 256
Study: 38914313

Group type: EXPERIMENTAL
Intervention: Energy restriction and exercise intervention
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 24
Study: 38914469

Group type: EXPERIMENTAL
Intervention: Endoscopic lung volume reduction (insertion of endobronchial valves)
Number of subjects: 19
Study: 38914481

Group type: EXPERIMENTAL
Intervention: High-intensity focused ultrasound (HIFU) treatment with a 30% increase in intensity
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High-intensity focused ultrasound (HIFU) treatment
Number of subjects: 60
Study: 38914694

Group type: EXPERIMENTAL
Intervention: 30 g ENSO 16
Number of subjects: 17

Group type: COMPARATOR
Intervention: 30 g glucose
Number of subjects: 17
Study: 38914876

Group type: EXPERIMENTAL
Intervention: Trazo/Gaba 2.5/25 mg t.i.d. for 8 weeks
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Trazo/Gaba 5/50 mg t.i.d. for 8 weeks
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Trazo/Gaba 10/100 mg t.i.d. for 8 weeks
Number of subjects: 240

Group type: COMPARATOR
Intervention: Gabapentin (Gaba)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo (PLB)
Number of subjects: 240
Study: 38914951

Group type: EXPERIMENTAL
Intervention: Primary DCB angioplasty
Number of subjects: 2270

Group type: COMPARATOR
Intervention: Primary stenting
Number of subjects: 2270
Study: 38914959

Group type: EXPERIMENTAL
Intervention: ICIs
Number of subjects: 1581

Group type: COMPARATOR
Intervention: anti-VEGF
Number of subjects: 1581
Study: 38914976

Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride 10% spray (experimental group)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Mepivacaine hydrochloride infiltration (control group)
Number of subjects: 136
Study: 38914974

Group type: EXPERIMENTAL
Intervention: Non-face-to-face consultations
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Face-to-face consultations
Number of subjects: 1000
Study: 38915038

Group type: EXPERIMENTAL
Intervention: Lever Positioning Manipulation (LPM) treatment, administered once every two days for a total of 12 times over 4 weeks.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham LPM treatment, administered during the same period as Group 1.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healthy controls (Group 3) without LPM treatment.
Number of subjects: 60
Study: 38915065

Group type: EXPERIMENTAL
Intervention: Triple therapy (sulfasalazine and hydroxychloroquine)
Number of subjects: 122

Group type: COMPARATOR
Intervention: TNFi (tumor necrosis factor inhibitor)
Number of subjects: 122
Study: 38915097

Group type: EXPERIMENTAL
Intervention: EVA Nexus surgical platform
Number of subjects: 250
Study: 38915103

Group type: EXPERIMENTAL
Intervention: Gamified Virtual Reality Environment (GVRE) treadmill rehabilitation program
Number of subjects: 8
Study: 38915106

Group type: EXPERIMENTAL
Intervention: Opioid taper support program with PA intervention at weeks 1, 2, 4, 8, 12, 16, and 20 after discharge.
Number of subjects: 73

Group type: COMPARATOR
Intervention: Usual care with standard hospital discharge instructions.
Number of subjects: 73
Study: 38915111

Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride (SDF)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 80
Study: 38915117

Group type: EXPERIMENTAL
Intervention: DynaFiT therapy (bortezomib, lenalidomide, dexamethasone; daratumumab for frail patients)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: DynaFiT therapy
Number of subjects: 90
Study: 38915115

Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg PO every other day
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg PO twice daily
Number of subjects: 90

Group type: COMPARATOR
Intervention: Traditional blood glucose lowering therapy + ramipril 10 mg PO
Number of subjects: 90
Study: 38915128

Group type: EXPERIMENTAL
Intervention: Exercise and patient education intervention (eight tailored one-to-one sessions with trained providers)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 200
Study: 38915130

Group type: EXPERIMENTAL
Intervention: Initial vaccination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increasing resident and staff vaccination uptake to a target goal of 90%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subsequent simulated removal of masking
Number of subjects: 0
Study: 38915151

Group type: EXPERIMENTAL
Intervention: Mistletoe extract (ME), injected subcutaneously three times a week for nine months
Number of subjects: 290

Group type: COMPARATOR
Intervention: Placebo, injected subcutaneously three times a week for nine months
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Mistletoe extract (ME)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study: 38915264

Group type: EXPERIMENTAL
Intervention: Care partner burden
Number of subjects: 431
Study: 38915356

Group type: EXPERIMENTAL
Intervention: EHR embedded goal setting and preference survey with telephonic nurse care management for 6 months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Delayed intervention control (EHR embedded survey after 6 months)
Number of subjects: 100
Study: 38915423

Group type: EXPERIMENTAL
Intervention: Omigapil at daily doses ranging from 0.02 to 0.08 mg/kg for 12 weeks after a 4-week vehicle run-in.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Omigapil
Number of subjects: 20
Study: 38915796

Group type: EXPERIMENTAL
Intervention: CTLA4-Ig and interleukin-2 (IL-2) therapy
Number of subjects: 4
Study: 38915856

Group type: EXPERIMENTAL
Intervention: 7 days of dietary nitrate supplementation (beetroot juice)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38915873

Group type: EXPERIMENTAL
Intervention: First-generation migratory status
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perinatal antibiotics usage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cesarean section birth
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 0
Study: 38916221

Group type: EXPERIMENTAL
Intervention: Virtual Reality Educational Program (VREP) - viewed a VR-based educational video on the surgical process, 7-10 days prior to surgery.
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Virtual Reality Educational Program (VREP)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Control group - received oral/written information about the anaesthetic-surgical process and remained in a playroom waiting for surgery.
Number of subjects: 241

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 241
Study: 38916223

Group type: EXPERIMENTAL
Intervention: Methylnaltrexone (0.15 mg/kg/d for 5 days)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Methylnaltrexone
Number of subjects: 105
Study: 38916263

Group type: EXPERIMENTAL
Intervention: Advance care planning discussions
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Discussion of end-of-life preferences
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Barriers to advance care planning
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Facilitators of advance care planning
Number of subjects: 22
Study: 38916283

Group type: EXPERIMENTAL
Intervention: HUAWEI GT 3 Pro smartwatch
Number of subjects: 23

Group type: COMPARATOR
Intervention: SphygmoCor
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: pOpmètre
Number of subjects: 23
Study: 38916421

Group type: EXPERIMENTAL
Intervention: AVT001
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 38916425

Group type: EXPERIMENTAL
Intervention: Home-delivered ART
Number of subjects: 155

Group type: COMPARATOR
Intervention: Clinic-based ART
Number of subjects: 155
Study: 38916429

Group type: EXPERIMENTAL
Intervention: DNA-HIV-PT123 vaccine with AS01B adjuvant
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: DNA-HIV-PT123 vaccine with MF59 adjuvant
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Low-dose protein/adjuvant with AS01B
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Co-administration of DNA with AS01B-adjuvanted bivalent Env gp120
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: AS01B-adjuvanted regimens
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: All intervention groups
Number of subjects: 400
Study: 38916700

Group type: EXPERIMENTAL
Intervention: DCISionRT test
Number of subjects: 2496
Study: 38916717

Group type: EXPERIMENTAL
Intervention: Vericiguat (10 mg target dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vericiguat
Number of subjects: 0
Study: 38916753

Group type: EXPERIMENTAL
Intervention: Intervention not specified in the abstract
Number of subjects: 47
Study: 38916892

Group type: EXPERIMENTAL
Intervention: Subcutaneous buprenorphine
Number of subjects: 428

Group type: COMPARATOR
Intervention: Sublingual buprenorphine-naloxone
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 428
Study: 38917081

Group type: EXPERIMENTAL
Intervention: Early assessment and intervention by a dedicated Health and Social Care Professionals (HSCP) team in the ED
Number of subjects: 353

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 353
Study: 38917099

Group type: EXPERIMENTAL
Intervention: Counseling for family planning at EPI units
Number of subjects: 1421
Study: 38917111

Group type: EXPERIMENTAL
Intervention: Video directly observed therapy (VDOT) for hydroxyurea
Number of subjects: 100000

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 100000
Study: 38917212

Group type: EXPERIMENTAL
Intervention: Frailty assessment using Clinical Frailty Scale
Number of subjects: 0
Study: 38917366

Group type: EXPERIMENTAL
Intervention: Esmethadone (REL-1017)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard antidepressants
Number of subjects: 0
Study: 38917371

Group type: EXPERIMENTAL
Intervention: Eflornithine (IWILFIN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: External Control (derived from Study ANBL0032)
Number of subjects: 0
Study: 38917400

Group type: EXPERIMENTAL
Intervention: Survivorship Education (SE)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Mindful Awareness Practices (MAPs)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Waitlist Control (WLC)
Number of subjects: 247